Use Cases
Sexual Health
Libido and Sexual Function
One of the few categories where the leading compound is FDA approved — and where its close relative is a clear example of what unselective signalling costs.
BModerate Human EvidenceReviewed September 1, 2026
Compounds used for this goal
The reason
Why people use it
- Low desire that is not explained by erectile mechanics is the specific complaint, since PT-141 acts centrally on melanocortin pathways rather than on blood flow.
- Bremelanotide is approved in the United States for hypoactive sexual desire disorder in premenopausal women, so the mechanism is genuinely established.
- Gonadorelin is discussed for maintaining endogenous hormone signalling rather than for desire directly.
The evidence
What the research shows
- Bremelanotide has randomised placebo-controlled trials supporting its approved indication, with modest average effect sizes and high nausea rates.
- Melanotan II shares the melanocortin mechanism but is far less selective, and its documented effects include nausea, spontaneous erections, darkening of moles and reports of melanoma diagnoses following use.
- Gonadorelin's human pharmacology is well established for diagnostic and fertility use; the wellness applications discussed for it are not trial-supported.
- Selectivity is the whole lesson of this category: the same receptor family, two very different risk profiles.
Reported use
How it is reported to be used
- PT-141 is reported as an as-needed subcutaneous injection ahead of activity rather than as a daily compound, matching its approved use.
- Nausea within the first hour is the dominant reported effect and the main reason people stop.
- Melanotan II reporting focuses on tanning as much as sexual effects, which is exactly where the melanoma concern arises.
Our reading
Evidence verdict
BModerate Human EvidenceSeveral human trials exist, but they are limited in size, duration or consistency.
Moderate human evidence for bremelanotide in its approved indication; Melanotan II carries real documented harm and should not be treated as its equivalent.
Before you read further
Cautions and open questions
- Melanotan II has been associated in case reports with changes in existing moles and with melanoma; this is not a theoretical risk.
- Bremelanotide's label includes blood pressure effects and cautions against use in uncontrolled hypertension or cardiovascular disease.
- Low libido is frequently driven by medication, thyroid or hormonal issues, depression or relationship factors — all of which need identifying first.
Sources
Referenced research
- Randomised controlled trial
Bremelanotide for hypoactive sexual desire disorder: randomised trials
- Observational study
Melanotan II: melanoma and adverse event case reports
Educational content only. This page is not medical advice, a protocol or an individualised dosing recommendation. Reported use patterns summarise published literature and community reporting; they are not verified clinical cases and are not endorsements. Speak to a qualified healthcare professional about your own health.
All use cases